

Biobanking Market by Specimen Type (Blood Products, Solid Tissue, Cell Lines, Nucleic Acid, and Others), by Type of Biobank (Population-based Biobanks, and Disease-oriented Biobanks), By Ownership (National/regional agency, Non-profit Organization, Universities, and Private Organization), by Application (Therapeutics, and Research) and End User (Academic Institutes, and Pharma & Biotech Companies): Global Opportunity Analysis and Industry Forecast, 2021—2028

<https://marketpublishers.com/r/B65D47DBE0BEN.html>

Date: June 2021

Pages: 291

Price: US\$ 6,168.00 (Single User License)

ID: B65D47DBE0BEN

Abstracts

The global biobanking market was valued at \$42,104.30 million in 2020, and is estimated to reach \$69,518.70 million by 2028, growing at a CAGR of 6.2% from 2021 to 2028.

Biobank is a biorepository meant to collect and preserve biological materials that are used for diagnosis, biodiversity studies, and research. In addition, it is used to support the research of the most common types of genetic disorders to develop personalized medicines and to maintain and update the database of diseases related to aging. It is a process of collecting different samples of body fluids or tissue and store for further use in research by pharmaceutical and biotechnology companies.

Rise in funding from private & government organizations to biobanking and increase in application areas of bio banked samples are the major factors that drive the growth of the global biobanking market. Moreover, upsurge in the incidence of diseases such as

cancer significantly contributes toward the market growth, owing to the fact that bio banked specimens are used in the treatment of several chronic diseases.

For instance, in April 2021, U.S. National Cancer Institute Cancer (NCI), launched Moonshot SM Biobank to accelerate research for the treatment of cancer. However, ethical issues related to biobanking and lack of awareness about it are expected to impede the market growth. On the contrary, advancements in stem cell research and unmet medical needs in emerging nations are anticipated to provide lucrative opportunity for market expansion.

Rise in genomic research activities acts as a key driving force of the global market. Furthermore, the government is taking multiple initiatives to support regenerative medicine research, which is expected to boost the market growth. Moreover, in 2021, the SingHealth Duke-NUS Academic Medical Centre launched advanced regenerative medicine and introduced cellular therapy to enhance patient care. The project aims to explore regenerative cell therapy for the treatment of blood cancers, heart failure, and eye degeneration.

Furthermore, the increase in demand for cost-effective drug delivery & development accelerates the market growth. Furthermore, there is an increase in the usage of human biospecimens in cohort studies. Number of registered clinical studies with the National Institutes of Health (NIH) increased from 181,305 in 2014 to 262,445 in 2017. A substantial number of large ongoing cohort studies related to precision medicine have fomented the establishment of population-based banks.

The surge in advancement in R&D for biobanking, is the key factor for the growth of the market. For instance, in February 2021, Cincinnati Children's Hospital Medical Center collaborated with Down Syndrome Achieves and launched a research biobank. It serves as a central repository for bio specimens which was donated by the patient having Down syndrome.

The global biobanking market is segmented into specimen type, type of biobank, ownership, application, end user, and region. By specimen type, the market is categorized into blood products, solid tissue, cell lines, nucleic acid, and others. By type of biobank, the market is bifurcated into population-based biobank and disease-oriented biobank. By ownership, it is divided into a national/regional agency, non-profit organization, universities, and private organization.

The applications covered in the study include therapeutic and research. By end user,

the market is bifurcated into academic institution and pharma & biotech companies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global biobanks market are BioIVT & Elevating Science, Geneticist Inc, Firalis S.A., AMS biotechnology Ltd. (AMSBIO LLC), and US Biolab Corporation, Inc., ProteoGenex, Inc., Cureline, Inc., Bay Biosciences LLC, CTI Biotech, and Boca Biolistics.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global biobanking market to identify the prevailing opportunities.

This study presents the competitive landscape of the global market to predict the competitive environment across geographies.

Comprehensive analysis of factors that drive and restrict the market growth is provided.

Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

By Specimen Type

Blood products

Solid tissue

Cell lines

Nucleic acid

Others

By Application

Therapeutic

Research

By Type of Biobank

Population-based biobanks

Disease-oriented biobanks

By Ownership

National/regional agencies

Nonprofit organization

Universities

Private Organization

By End User

Academic Institutions

Pharma & Biotech Companies

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

The key players profiled in this report are as follows:

BioIVT & Elevating Science

Geneticist Inc.

Firalis S.A.

AMS biotechnology Ltd. (AMSBIO LLC)

US Biolab Corporation, Inc.

ProteoGenex, Inc.

Cureline, Inc.

Bay Biosciences LLC

CTI Biotech

Boca Biolistics

Contents

CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
- 1.4.Research methodology
 - 1.1.1.Secondary research
 - 1.1.2.Primary research
 - 1.1.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

- 2.1.Key findings of the study
- 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

- 3.1.Market definition and scope
- 3.2.Key findings
 - 3.2.1.Top investment pockets
 - 3.2.2.Top winning strategies
- 3.3.Porter's five forces analysis
 - 3.3.1.Top player positioning
- 3.4.Market dynamics
 - 3.4.1.Drivers, restraints, and opportunity
 - 3.4.2.Drivers
 - 3.4.2.1.Rise in funds for biobanks
 - 3.4.2.2.Increase in R&D activities for application of biobank specimens
 - 3.4.2.3.Surge in prevalence of fatal chronic diseases
 - 3.4.3.Restraints
 - 3.4.3.1.Legal and ethical issues of biobanking
 - 3.4.3.2.Lack of awareness toward biobanking
 - 3.4.4.Opportunity
 - 3.4.4.1.High growth potential in developing countries
- 3.5.Impact of COVID-19 on biobanking market
 - 3.5.1.Overview
 - 3.5.2.Impact analysis

3.5.3.List of largest government regulated biobanks across the globe

CHAPTER 4: BIOBANKING MARKET, BY SPECIMEN TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Blood products

4.2.1.Key market trends and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis, by country

4.3.Solid tissues

4.3.1.Key market trends and opportunities

4.3.2.Market size and forecast, by region

4.3.3.Market analysis, by country

4.4.Cell lines

4.4.1.Key market trends and opportunities

4.4.2.Market size and forecast, by region

4.4.3.Market analysis, by country

4.5.Nucleic acid

4.5.1.Key market trends and opportunities

4.5.2.Market size and forecast, by region

4.5.3.Market analysis, by country

4.6.Others

4.6.1.Key market trends and opportunities

4.6.2.Market size and forecast, by region

4.6.3.Market analysis, by country

CHAPTER 5: BIOBANKING MARKET, BY TYPE OF BIOBANK

5.1.Overview

5.1.1.Market size and forecast

5.2.Population-based biobanks

5.2.1.Key market trends and opportunities

5.2.2.Market size and forecast, by region

5.2.3.Market analysis, by country

5.3.Disease-oriented biobanks

5.3.1.Key market trends and opportunities

5.3.2.Market size and forecast, by region

5.3.3.Market analysis, by country

CHAPTER 6: BIOBANKING MARKET, BY OWNERSHIP

6.1. Overview

6.1.1. Market size and forecast

6.2. National/regional agency

6.2.1. Key market trends and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market analysis, by country

6.2.4. National/regional agency, by end user

6.3. Non-profit organization

6.3.1. Key market trends and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market analysis, by country

6.3.4. Non-profit organization, by end user

6.4. Universities

6.4.1. Key market trends and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market analysis, by country

6.4.4. University, by end user

6.5. Private organization

6.5.1. Key market trends and opportunities

6.5.2. Market size and forecast, by region

6.5.3. Market analysis, by country

6.5.4. Private Organization, by end user

CHAPTER 7: BIOBANKING MARKET, BY APPLICATION

7.1. Overview

7.1.1. Market size and forecast

7.2. Therapeutic

7.2.1. Key market trends and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market analysis, by country

7.3. Research

7.3.1. Key market trends and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market analysis, by country

CHAPTER 8: BIOBANKING MARKET, BY END USER

8.1. Overview

8.1.1. Market size and forecast

8.2. Academic institutions

8.2.1. Key market trends and opportunities

8.2.2. Market size and forecast, by region

8.2.3. Market analysis, by country

8.3. Pharma & biotech companies

8.3.1. Key market trends and opportunities

8.3.2. Market size and forecast, by region

8.3.3. Market analysis, by country

CHAPTER 9: BIOBANKING MARKET, BY REGION

9.1. Overview

9.1.1. Market size and forecast

9.2. North America

9.2.1. Key market trends, growth factors, and opportunities

9.2.2. North America market size and forecast, by country

9.2.2.1. U.S. biobanking market size and forecast, by specimen type

9.2.2.2. U.S. biobanking market size and forecast, by type of biobank

9.2.2.3. U.S. biobanking market size and forecast, by ownership

9.2.2.4. U.S. biobanking market size and forecast, by application

9.2.2.5. US biobanking market size and forecast, by End User

9.2.2.6. Canada biobanking market size and forecast, by specimen type

9.2.2.7. Canada biobanking market size and forecast, by type of biobank

9.2.2.8. Canada biobanking market size and forecast, by ownership

9.2.2.9. Canada biobanking market size and forecast, by application

9.2.2.10. Canada biobanking market size and forecast, by End User

9.2.2.11. Mexico biobanking market size and forecast, by specimen type

9.2.2.12. Mexico biobanking market size and forecast, by type of biobank

9.2.2.13. Mexico biobanking market size and forecast, by ownership

9.2.2.14. Mexico biobanking market size and forecast, by application

9.2.2.15. Mexico biobanking market size and forecast, by End User

9.2.3. North America market size and forecast, by specimen type

9.2.4. North America market size and forecast, by type of biobank

9.2.5. North America biobanking market size and forecast, by ownership

9.2.6. North America biobanking market size and forecast, by application

9.2.7.North America biobanking market size and forecast, by End User

9.3.Europe

9.3.1.Key market trends, growth factors, and opportunities

9.3.2.Europe market size and forecast, by country

9.3.2.1.Germany biobanking market size and forecast, by specimen type

9.3.2.2.Germany biobanking market size and forecast, by type of biobank

9.3.2.3.Germany biobanking market size and forecast, by ownership

9.3.2.4.Germany biobanking market size and forecast, by application

9.3.2.5.Germany biobanking market size and forecast, by End User

9.3.2.6.France biobanking market size and forecast, by specimen type

9.3.2.7.France biobanking market size and forecast, by type of biobank

9.3.2.8.France biobanking market size and forecast, by ownership

9.3.2.9.France biobanking market size and forecast, by application

9.3.2.10.France biobanking market size and forecast, by End User

9.3.2.11.UK biobanking market size and forecast, by specimen type

9.3.2.12.UK biobanking market size and forecast, by type of biobank

9.3.2.13.UK biobanking market size and forecast, by ownership

9.3.2.14.UK biobanking market size and forecast, by application

9.3.2.15.UK biobanking market size and forecast, by End User

9.3.2.16.Italy biobanking market size and forecast, by specimen type

9.3.2.17.Italy biobanking market size and forecast, by type of biobank

9.3.2.18.Italy biobanking market size and forecast, by ownership

9.3.2.19.Italy biobanking market size and forecast, by application

9.3.2.20.Italy biobanking market size and forecast, by End User

9.3.2.21.Spain biobanking market size and forecast, by specimen type

9.3.2.22.Spain biobanking market size and forecast, by type of biobank

9.3.2.23.Spain biobanking market size and forecast, by ownership

9.3.2.24.Spain biobanking market size and forecast, by application

9.3.2.25.Spain biobanking market size and forecast, by End User

9.3.2.26.Rest of Europe biobanking market size and forecast, by specimen type

9.3.2.27.Rest of Europe biobanking market size and forecast, by type of biobank

9.3.2.28.Rest of Europe biobanking market size and forecast, by ownership

9.3.2.29.Rest of Europe biobanking market size and forecast, by application

9.3.2.30.Rest of Europe biobanking market size and forecast, by End User

9.3.3.Europe market size and forecast, by specimen type

9.3.4.Europe market size and forecast, by type of biobank

9.3.5.Europe biobanking market size and forecast, by ownership

9.3.6.Europe biobanking market size and forecast, by application

9.3.7.Europe biobanking market size and forecast, by End User

9.4.Asia-Pacific

9.4.1.Key market trends, growth factors, and opportunities

9.4.2.Asia-Pacific market size and forecast, by country

9.4.2.1.Japan biobanking market size and forecast, by specimen type

9.4.2.2.Japan biobanking market size and forecast, by type of biobank

9.4.2.3.Japan biobanking market size and forecast, by ownership

9.4.2.4.Japan biobanking market size and forecast, by application

9.4.2.5.Japan biobanking market size and forecast, by End User

9.4.2.6.China biobanking market size and forecast, by specimen type

9.4.2.7.China biobanking market size and forecast, by type of biobank

9.4.2.8.China biobanking market size and forecast, by ownership

9.4.2.9.China biobanking market size and forecast, by application

9.4.2.10.China biobanking market size and forecast, by End User

9.4.2.11.India biobanking market size and forecast, by specimen type

9.4.2.12.India biobanking market size and forecast, by type of biobank

9.4.2.13.India biobanking market size and forecast, by ownership

9.4.2.14.India biobanking market size and forecast, by application

9.4.2.15.India biobanking market size and forecast, by End User

9.4.2.16.Australia biobanking market size and forecast, by specimen type

9.4.2.17.Australia biobanking market size and forecast, by type of biobank

9.4.2.18.Australia biobanking market size and forecast, by ownership

9.4.2.19.Australia biobanking market size and forecast, by application

9.4.2.20.Australia biobanking market size and forecast, by End User

9.4.2.21.Rest of Asia-Pacific biobanking market size and forecast, by specimen type

9.4.2.22.Rest of Asia-Pacific biobanking market size and forecast, by type of biobank

9.4.2.23.Rest of Asia-Pacific biobanking market size and forecast, by ownership

9.4.2.24.Rest of Asia-Pacific biobanking market size and forecast, by application

9.4.2.25.Rest of Asia-Pacific biobanking market size and forecast, by End User

9.4.3.Asia-Pacific market size and forecast, by specimen type

9.4.4.Asia-Pacific market size and forecast, by type of biobank

9.4.5.Asia-Pacific biobanking market size and forecast, by ownership

9.4.6.Asia-Pacific biobanking market size and forecast, by application

9.4.7.Asia-Pacific biobanking market size and forecast, by End User

9.5.LAMEA

9.5.1.Key market trends, growth factors, and opportunities

9.5.2.LAMEA market size and forecast, by country

9.5.2.1.Brazil biobanking market size and forecast, by specimen type

9.5.2.2.Brazil biobanking market size and forecast, by type of biobank

9.5.2.3.Brazil biobanking market size and forecast, by ownership

- 9.5.2.4. Brazil biobanking market size and forecast, by application
- 9.5.2.5. Brazil biobanking market size and forecast, by End User
- 9.5.2.6. Saudi Arabia biobanking market size and forecast, by specimen type
- 9.5.2.7. Saudi Arabia biobanking market size and forecast, by type of biobank
- 9.5.2.8. Saudi Arabia biobanking market size and forecast, by ownership
- 9.5.2.9. Saudi Arabia biobanking market size and forecast, by application
- 9.5.2.10. Saudi Arabia biobanking market size and forecast, by End User
- 9.5.2.11. South Africa biobanking market size and forecast, by specimen type
- 9.5.2.12. South Africa biobanking market size and forecast, by type of biobank
- 9.5.2.13. South Africa biobanking market size and forecast, by ownership
- 9.5.2.14. South Africa biobanking market size and forecast, by application
- 9.5.2.15. South Africa biobanking market size and forecast, by End User
- 9.5.2.16. Rest of LAMEA biobanking market size and forecast, by specimen type
- 9.5.2.17. Rest of LAMEA biobanking market size and forecast, by type of biobank
- 9.5.2.18. Rest of LAMEA biobanking market size and forecast, by ownership
- 9.5.2.19. Rest of LAMEA biobanking market size and forecast, by application
- 9.5.2.20. Rest of LAMEA biobanking market size and forecast, by End User
- 9.5.3. LAMEA market size and forecast, by specimen type
- 9.5.4. LAMEA market size and forecast, by type of biobank
- 9.5.5. LAMEA biobanking market size and forecast, by ownership
- 9.5.6. LAMEA biobanking market size and forecast, by application
- 9.5.7. LAMEA biobanking market size and forecast, by End User

CHAPTER 10: COMPANY PROFILES

10.1. AMS BIOTECHNOLOGY LTD. (AMSBIO LLC)

- 10.1.1. Company overview
- 10.1.2. Company snapshot
- 10.1.3. Operating business segments
- 10.1.4. Product portfolio

10.2. BAY BIOSCIENCES LLC

- 10.2.1. Company overview
- 10.2.2. Company snapshot
- 10.2.3. Operating business segments
- 10.2.4. Product portfolio

10.3. BIOIVT & ELEVATING SCIENCE

- 10.3.1. Company overview
- 10.3.2. Company snapshot
- 10.3.3. Operating business segments

- 10.3.4.Product portfolio
- 10.3.5.Key strategic moves and developments
- 10.4.BOCA BIOLISTICS
 - 10.4.1.Company overview
 - 10.4.2.Company snapshot
 - 10.4.3.Operating business segments
 - 10.4.4.Product portfolio
- 10.5.CTI BIOTECH
 - 10.5.1.Company overview
 - 10.5.2.Company snapshot
 - 10.5.3.Operating business segments
 - 10.5.4.Product portfolio
 - 10.5.5.Key strategic moves and developments
- 10.6.CURELINE, INC.
 - 10.6.1.Company overview
 - 10.6.2.Company snapshot
 - 10.6.3.Operating business segments
 - 10.6.4.Product portfolio
 - 10.6.5.Key strategic moves and developments
- 10.7.FIRALIS S.A.
 - 10.7.1.Company overview
 - 10.7.2.Company snapshot
 - 10.7.3.Operating business segments
 - 10.7.4.Product portfolio
 - 10.7.5.Key strategic moves and developments
- 10.8.GENETICIST INC.
 - 10.8.1.Company overview
 - 10.8.2.Company snapshot
 - 10.8.3.Operating business segments
 - 10.8.4.Product portfolio
- 10.9.PROTEOGENEX, INC.
 - 10.9.1.Company overview
 - 10.9.2.Company snapshot
 - 10.9.3.Operating business segments
 - 10.9.4.Product portfolio
- 10.10.US BIOLAB CORPORATION, INC.
 - 10.10.1.Company overview
 - 10.10.2.Company snapshot
 - 10.10.3.Operating business segments

10.10.4.Product portfolio

List Of Tables

LIST OF TABLES

TABLE 01.LIST OF LARGEST GOVERNMENT REGULATED BIOBANKS ACROSS THE GLOBE

TABLE 02.GLOBAL BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 03.BIOBANKING MARKET REVENUE FOR BLOOD PRODUCTS, BY REGION, 2020–2028(\$MILLION)

TABLE 04.BIOBANKING MARKET REVENUE FOR SOLID TISSUE, BY REGION, 2020–2028(\$MILLION)

TABLE 05.BIOBANKING MARKET REVENUE FOR CELL LINES, BY REGION, 2020–2028(\$MILLION)

TABLE 06.BIOBANKING MARKET REVENUE FOR NUCLEIC ACID SAMPLES, BY REGION, 2020–2028(\$MILLION)

TABLE 07.BIOBANKING MARKET REVENUE FOR OTHERS, BY REGION, 2020–2028(\$MILLION)

TABLE 08.BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028(\$MILLION)

TABLE 09.POPULATION-BASED BIOBANKING MARKET REVENUE, BY REGION, 2020–2028(\$MILLION)

TABLE 10.DISEASE-ORIENTED BIOBANKING MARKET REVENUE, BY REGION, 2020–2028(\$MILLION)

TABLE 11.GLOBAL BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028(\$MILLION)

TABLE 12.BIOBANKING MARKET REVENUE FOR NATIONAL/REGIONAL AGENCY, BY REGION, 2020–2028(\$MILLION)

TABLE 13.NATIONAL/REGIONAL AGENCY, BY END USER, 2020–2028(\$MILLION)

TABLE 14.BIOBANKING MARKET REVENUE FOR NON-PROFIT ORGANIZATION, BY REGION, 2020–2028(\$MILLION)

TABLE 15.NON-PROFIT ORGANIZATION, BY END USER, 2020–2028(\$MILLION)

TABLE 16.BIOBANKING MARKET REVENUE FOR UNIVERSITY, BY REGION, 2020–2028(\$MILLION)

TABLE 17.UNIVERSITY, BY END USER, 2020–2028(\$MILLION)

TABLE 18.BIOBANKING MARKET REVENUE FOR PRIVATE ORGANIZATION, BY REGION, 2020–2028(\$MILLION)

TABLE 19.PRIVATE ORGANIZATION, BY END USER, 2020–2028(\$MILLION)

TABLE 20.GLOBAL BIOBANKING MARKET REVENUE, BY APPLICATION,

2020–2028(\$MILLION)

TABLE 21.BIOBANKING MARKET REVENUE FOR THERAPEUTIC, BY REGION, 2020–2028(\$MILLION)

TABLE 22.BIOBANKING MARKET REVENUE FOR RESEARCH, BY REGION, 2020–2028(\$MILLION)

TABLE 23.GLOBAL BIOBANKING MARKET REVENUE, BY END USER, 2020–2028(\$MILLION)

TABLE 24.BIOBANKING MARKET REVENUE FOR ACADEMIC INSTITUTIONS, BY REGION, 2020–2028(\$MILLION)

TABLE 25.BIOBANKING MARKET REVENUE FOR PHARMA & BIOTECH COMPANIES, BY REGION, 2020–2028(\$MILLION)

TABLE 26.BIOBANKING MARKET REVENUE, BY REGION, 2020–2028 (\$MILLION)

TABLE 27.NORTH AMERICA BIOBANKING MARKET REVENUE, BY COUNTRY, 2020–2028 (\$MILLION)

TABLE 28.U.S. BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 29.U.S. BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 30.U.S. BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 31.U.S. BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 32.US BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 33.CANADA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 34.CANADA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 35.CANADA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 36.CANADA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 37.CANADA BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 38.MEXICO BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 39.MEXICO BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 40.MEXICO BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028

(\$MILLION)

TABLE 41.MEXICO BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 42.MEXICO BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 43.NORTH AMERICA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 44.NORTH AMERICA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 45.NORTH AMERICA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 46.NORTH AMERICA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 47.NORTH AMERICA BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 48.EUROPE BIOBANKING MARKET REVENUE, BY COUNTRY, 2020–2028 (\$MILLION)

TABLE 49.GERMANY BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 50.GERMANY BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 51.GERMANY BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 52.GERMANY BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 53.GERMANY BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 54.FRANCE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 55.FRANCE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 56.FRANCE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 57.FRANCE BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 58.FRANCE BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 59.UK BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 60.UK BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 61.UK BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 62.UK BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 63.UK BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 64.ITALY BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 65.ITALY BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 66.ITALY BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 67.ITALY BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 68.ITALY BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 69.SPAIN BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 70.SPAIN BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 71.SPAIN BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 72.SPAIN BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 73.SPAIN BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 74.REST OF EUROPE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 75.REST OF EUROPE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 76.REST OF EUROPE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 77.REST OF EUROPE BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 78.REST OF EUROPE BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 79.EUROPE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE,

2020–2028 (\$MILLION)

TABLE 80.EUROPE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK,
2020–2028 (\$MILLION)

TABLE 81.EUROPE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028
(\$MILLION)

TABLE 82.EUROPE BIOBANKING MARKET REVENUE, BY APPLICATION,
2020–2028 (\$MILLION)

TABLE 83.EUROPE BIOBANKING MARKET REVENUE, BY END USER, 2020–2028
(\$MILLION)

TABLE 84.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY COUNTRY,
2020–2028 (\$MILLION)

TABLE 85.JAPAN BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE,
2020–2028 (\$MILLION)

TABLE 86.JAPAN BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK,
2020–2028 (\$MILLION)

TABLE 87.JAPAN BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028
(\$MILLION)

TABLE 88.JAPAN BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028
(\$MILLION)

TABLE 89.JAPAN BIOBANKING MARKET REVENUE, BY END USER, 2020–2028
(\$MILLION)

TABLE 90.CHINA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE,
2020–2028 (\$MILLION)

TABLE 91.CHINA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK,
2020–2028 (\$MILLION)

TABLE 92.CHINA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028
(\$MILLION)

TABLE 93.CHINA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028
(\$MILLION)

TABLE 94.CHINA BIOBANKING MARKET REVENUE, BY END USER, 2020–2028
(\$MILLION)

TABLE 95.INDIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE,
2020–2028 (\$MILLION)

TABLE 96.INDIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK,
2020–2028 (\$MILLION)

TABLE 97.INDIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028
(\$MILLION)

TABLE 98.INDIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028
(\$MILLION)

TABLE 99.INDIA BIOBANKING MARKET REVENUE, BY INDIA, 2020–2028
(\$MILLION)

TABLE 100.AUSTRALIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE,
2020–2028 (\$MILLION)

TABLE 101.AUSTRALIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK,
2020–2028 (\$MILLION)

TABLE 102.AUSTRALIA BIOBANKING MARKET REVENUE, BY OWNERSHIP,
2020–2028 (\$MILLION)

TABLE 103.AUSTRALIA BIOBANKING MARKET REVENUE, BY APPLICATION,
2020–2028 (\$MILLION)

TABLE 104.AUSTRALIA BIOBANKING MARKET REVENUE, BY END USER,
2020–2028 (\$MILLION)

TABLE 105.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY
SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 106.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY TYPE
OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 107.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY
OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 108.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY
APPLICATION, 2020–2028 (\$MILLION)

TABLE 109.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY END
USER, 2020–2028 (\$MILLION)

TABLE 110.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE,
2020–2028 (\$MILLION)

TABLE 111.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY TYPE OF
BIOBANK, 2020–2028 (\$MILLION)

TABLE 112.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY OWNERSHIP,
2020–2028 (\$MILLION)

TABLE 113.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY APPLICATION,
2020–2028 (\$MILLION)

TABLE 114.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY END USER,
2020–2028 (\$MILLION)

TABLE 115.LAMEA BIOBANKING MARKET REVENUE, BY COUNTRY, 2020–2028
(\$MILLION)

TABLE 116.BRAZIL BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE,
2020–2028 (\$MILLION)

TABLE 117.BRAZIL BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK,
2020–2028 (\$MILLION)

TABLE 118.BRAZIL BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028

(\$MILLION)

TABLE 119.BRAZIL BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 120.BRAZIL BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 121.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 122.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 123.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 124.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 125.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 126.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 127.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 128.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 129.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 130.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 131.REST OF LAMEA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 132.REST OF LAMEA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 133.REST OF LAMEA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 134.REST OF LAMEA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 135.REST OF LAMEA BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 136.LAMEA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2020–2028 (\$MILLION)

TABLE 137.LAMEA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2020–2028 (\$MILLION)

TABLE 138.LAMEA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2020–2028 (\$MILLION)

TABLE 139.LAMEA BIOBANKING MARKET REVENUE, BY APPLICATION, 2020–2028 (\$MILLION)

TABLE 140.LAMEA BIOBANKING MARKET REVENUE, BY END USER, 2020–2028 (\$MILLION)

TABLE 141.AMSBIO: COMPANY SNAPSHOT

TABLE 142.AMSBIO: PRODUCT CATEGORY

TABLE 143.AMSBIO: PRODUCT PORTFOLIO

TABLE 144.BAY BIOSCIENCES: COMPANY SNAPSHOT

TABLE 145.BAY BIOSCIENCES: PRODUCT CATEGORY

TABLE 146.BAY BIOSCIENCES: PRODUCT PORTFOLIO

TABLE 147.BIOIVT: COMPANY SNAPSHOT

TABLE 148.BIOIVT: OPERATING SEGMENTS

TABLE 149.BIOIVT: PRODUCT PORTFOLIO

TABLE 150.BOCA BIOLISTICS: COMPANY SNAPSHOT

TABLE 151.BOCA BIOLISTICS: OPERATING SEGMENTS

TABLE 152.BOCA BIOLISTICS: PRODUCT PORTFOLIO

TABLE 153.CTI BIOTECH: COMPANY SNAPSHOT

TABLE 154.CTI BIOTECH: OPERATING SEGMENTS

TABLE 155.CTI BIOTECH: SERVICE PORTFOLIO

TABLE 156.CURELINE: COMPANY SNAPSHOT

TABLE 157.CURELINE: OPERATING SEGMENTS

TABLE 158.CURELINE: SERVICE PORTFOLIO

TABLE 159.FIRALIS: COMPANY SNAPSHOT

TABLE 160.FIRALIS: OPERATING SEGMENTS

TABLE 161.FIRALIS: SERVICE PORTFOLIO

TABLE 162.GENETICIST: COMPANY SNAPSHOT

TABLE 163.GENETICIST COMPANY: SEGMENTS

TABLE 164.GENETICIST: PRODUCT PORTFOLIO

TABLE 165.PROTEOGENEX: COMPANY SNAPSHOT

TABLE 166.PROTEOGENEX: OPERATING SEGMENTS

TABLE 167.PROTEOGENEX: PRODUCT PORTFOLIO

TABLE 168.US BIOLAB: COMPANY SNAPSHOT

TABLE 169.US BIOLAB: OPERATING SEGMENTS

TABLE 170.US BIOLAB: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

- FIGURE 01.GLOBAL BIOBANKING MARKET SEGMENTATION
- FIGURE 02.TOP INVESTMENT POCKETS
- FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
- FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
- FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
- FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
- FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 08.HIGH THREAT OF NEW ENTRANTS
- FIGURE 09.MODERATE THREAT OF SUBSTITUTION
- FIGURE 10.MODERATE COMPETITIVE RIVALRY
- FIGURE 11.TOP PLAYER POSITIONING, 2020
- FIGURE 12.DRIVERS, RESTRAINTS, AND OPPORTUNITY
- FIGURE 13.BIOBANKING MARKET REVENUE FOR BLOOD PRODUCTS, BY COUNTRY, 2020–2028(%)
- FIGURE 14.BIOBANKING MARKET REVENUE FOR SOLID TISSUE, BY COUNTRY, 2020–2028(%)
- FIGURE 15.BIOBANKING MARKET REVENUE FOR CELL LINES, BY COUNTRY, 2020–2028(%)
- FIGURE 16.BIOBANKING MARKET REVENUE FOR NUCLEIC ACID SAMPLES, BY COUNTRY, 2020–2028(%)
- FIGURE 17.BIOBANKING MARKET REVENUE FOR OTHERS, BY COUNTRY, 2020–2028(%)
- FIGURE 18.POPULATION-BASED BIOBANKING MARKET REVENUE, BY COUNTRY, 2020–2028(%)
- FIGURE 19.DISEASE-ORIENTED BIOBANKING REVENUE, BY COUNTRY, 2020–2028(%)
- FIGURE 20.BIOBANKING MARKET REVENUE FOR NATIONAL/REGIONAL AGENCY, BY COUNTRY, 2020–2028(%)
- FIGURE 21.BIOBANKING MARKET REVENUE FOR NON-PROFIT ORGANIZATION, BY COUNTRY, 2020–2028(%)
- FIGURE 22.BIOBANKING MARKET REVENUE FOR UNIVERSITY, BY COUNTRY, 2020–2028(%)
- FIGURE 23.BIOBANKING MARKET REVENUE FOR PRIVATE ORGANIZATION, BY COUNTRY, 2020–2028(%)
- FIGURE 24.BIOBANKING MARKET REVENUE FOR THERAPEUTIC, BY COUNTRY,

2020–2028(%)

FIGURE 25. BIOBANKING MARKET REVENUE FOR RESEARCH, BY COUNTRY,
2020–2028(%)

FIGURE 26. BIOBANKING MARKET REVENUE FOR ACADEMIC INSTITUTIONS, BY
COUNTRY, 2020–2028(%)

FIGURE 27. BIOBANKING MARKET REVENUE FOR PHARMA & BIOTECH
COMPANIES, BY COUNTRY, 2020–2028(%)

I would like to order

Product name: Biobanking Market by Specimen Type (Blood Products, Solid Tissue, Cell Lines, Nucleic Acid, and Others), by Type of Biobank (Population-based Biobanks, and Disease-oriented Biobanks), By Ownership (National/regional agency, Non-profit Organization, Universities, and Private Organization), by Application (Therapeutics, and Research) and End User (Academic Institutes, and Pharma & Biotech Companies): Global Opportunity Analysis and Industry Forecast, 2021—2028

Product link: <https://marketpublishers.com/r/B65D47DBE0BEN.html>

Price: US\$ 6,168.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B65D47DBE0BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970